This dual anti-CD20/anti-CD47 approach has provided convincing clinical results and is still being extensively evaluated, both pre-clinically and clinically, in B-cell lymphoma (7). This evidence concerns the gene CD47 and B-cell non-Hodgkin lymphoma.